Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $62.8 million.

  • Krystal Biotech's Operating Expenses rose 2626.6% to $62.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $228.0 million, marking a year-over-year increase of 143.11%. This contributed to the annual value of $227.8 million for FY2025, which is 136.5% up from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's Operating Expenses is $62.8 million, which was up 2626.6% from $56.4 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Operating Expenses ranged from a high of $62.8 million in Q4 2025 and a low of $14.4 million during Q1 2021
  • Its 5-year average for Operating Expenses is $41.3 million, with a median of $43.9 million in 2023.
  • In the last 5 years, Krystal Biotech's Operating Expenses soared by 24990.59% in 2022 and then tumbled by 807.38% in 2025.
  • Quarter analysis of 5 years shows Krystal Biotech's Operating Expenses stood at $21.9 million in 2021, then skyrocketed by 58.95% to $34.8 million in 2022, then increased by 11.86% to $38.9 million in 2023, then increased by 27.94% to $49.8 million in 2024, then increased by 26.27% to $62.8 million in 2025.
  • Its last three reported values are $62.8 million in Q4 2025, $56.4 million for Q3 2025, and $56.7 million during Q2 2025.